[JSNM]Therapy3: Neuroendocrine Tumor

Annual Scientific Meeting of the Japanese Society of Nuclear Medicine Program » [核医学]一般演題口演

Therapy3

Neuroendocrine Tumor

Fri. Sep 9, 2022 4:10 PM - 4:50 PM Room6 (Kyoto International Conference Center 2F RoomB-2)

Chair：Mana Yoshimura (Department of Radiology, Tokyo Medical University), Michihiro Nakayama (Department of Radiology, Asahikawa Medical University)

+Add all to schedule

[M1VIE1] The usefulness of the image evaluation at the 177Lu-DOTATATE therapy

Shigeyasu Sugawara¹、Tohru Shiga¹、Motoharu Hakozaki²、Ryo Yamakuni²、Hironori Suenaga²、Daichi Kuroiwa²、Osamu Hasegawa²、Hirofumi Sekino²、Shiro Ishii²、Hiroshi Ito^1,2、Noboru Oriuchi¹ (1.Advanced Clinical Research Center, Fukushima Medical University, Fukushima, Japan、2.Department of Radiology and Nuclear Medicine, Fukushima Medical University, Fukushima, Japan)

[M1VIE2] Questionnaire survey on the introduction status of the new PRRT drug (Lu-177 DOTATATE)

Yusuke Iizuka^1,2 (1.Department of Radiation Oncology, Shizuoka City Shizuoka Hospital、2.Department of radiation oncology and image-applied therapy, Graduate school of medicine, Kyoto University)

[M1VIE3] Our Experience with Peptide Receptor Radionuclide Therapy

Atsushi Yoshida、Shigeaki Higashiyama、Joji Kawabe (Department of Nuclear Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan)

[M1VIE4] Initial experience of Lu-177 DOTATATE PRRT in Kanazawa University Hospital

Anri Inaki、Hiroshi Wakabayashi、Tomo Hiromasa、Hiroshi Mori、Norihito Akatani、Shintaro Saitou、Takafumi Yamase、Daiki Kayano、Seigo Kinuya (Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Japan)